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http://www.biomedcentral.com/1471-2407/12/404RESEARCH ARTICLE Open AccessReverse translation of phase I biomarker findings
links the activity of angiotensin-(1–7) to
repression of hypoxia inducible factor-1α in
vascular sarcomas
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Background: In a phase I study of angiotensin-(1–7) [Ang-(1–7)], clinical benefit was associated with reduction in
plasma placental growth factor (PlGF) concentrations. The current study examines Ang-(1–7) induced changes in
biomarkers according to cancer type and investigates mechanisms of action engaged in vitro.
Methods: Plasma biomarkers were measured prior to Ang-(1–7) administration as well as 1, 2, 3, 4, and 6 hours
after treatment. Tests for interaction were performed to determine the impact of cancer type on angiogenic
hormone levels. If a positive interaction was detected, treatment-induced biomarker changes for individual cancer
types were assessed. To investigate mechanisms of action, in vitro growth assays were performed using a murine
endothelioma cell line (EOMA). PCR arrays were performed to identify and statistically validate genes that were
altered by Ang-(1–7) treatment in these cells.
Results: Tests for interaction controlled for dose cohort and clinical response indicated a significant impact of
cancer type on post-treatment VEGF and PlGF levels. Following treatment, PlGF levels decreased over time in
patients with sarcoma (P = .007). Treatment of EOMA cells with increasing doses of Ang-(1–7) led to significant
growth suppression at doses as low as 100 nM. PCR arrays identified 18 genes that appeared to have altered
expression after Ang-(1–7) treatment. Replicate analyses confirmed significant changes in 8 genes including
reduction in PlGF (P= .04) and hypoxia inducible factor 1α (HIF-1α) expression (P< .001).
Conclusions: Ang-(1–7) has clinical and pre-clinical activity for vascular sarcomas that is linked to reduced HIF-1α
and PlGF expression.
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Angiotensin-(1–7) [Ang-(1–7)] is a component of the
renin-angiotensin system that has demonstrated anti-
angiogenic activity in pre-clinical models [1-6]. Murine
xenograft models have demonstrated that Ang-(1–7)
exerts anti-angiogenic effects in a variety of cancer types
[7,8]. While this drug has shown a broad spectrum of* Correspondence: wpetty@wfubmc.edu
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reproduction in any medium, provided the oractivity, the specific angiogenic hormone suppressed by
Ang-(1–7) treatment varies according to the type of can-
cer being treated. In some cancer cell lines, vascular
endothelial growth factor (VEGF) is suppressed by treat-
ment while in others, placental growth factor (PlGF) is
suppressed [7,8].
A phase I study was conducted to examine the toler-
ability and activity of Ang-(1–7) for the treatment of
patients with advanced solid tumors refractory to stand-
ard therapy [9]. The tolerability was very good and clin-
ical benefit was observed in four patients. Two of these
patients had metastatic sarcomas. The group of patients
with clinical benefit demonstrated a reduction in plasmad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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trast, PlGF levels did not significantly change over time
in the group of patients without clinical benefit. Levels
of VEGF did not significantly change over time in either
group [9].
The signaling changes that trigger repression of PlGF
or VEGF have not been well characterized. The clinical
observation of PlGF suppression in patients with clinical
benefit has compelled us to determine how this occurs
[9]. To investigate this phenomenon, the current study
was undertaken to reverse-translate the clinical findings
back to a preclinical in vitro model. This was ac-
complished by identifying the cancer type most likely to
achieve a biomarker response and then evaluating changes
in angiogenic signaling following Ang-(1–7) treatment of
a related cancer cell line.
Since Ang-(1–7) exerts its anti-angiogenic activity
through regulation of different angiogenic hormones de-
pending on cancer type in pre-clinical models, it is pos-
sible that clinical changes in plasma anti-angiogenic
hormones could vary depending on the type of cancer
treated [7,8]. Repression of VEGF has been identified in
pre-clinical models, but reduction of plasma VEGF levels
was not documented in analysis of the phase I study [9].
If changes in VEGF occurred only in certain cancer
types, a significant effect on VEGF could have been
underestimated by the analysis.
The current study tests whether the type of cancer
being treated impacted the likelihood of achieving a bio-
marker response in the phase I study. Changes in VEGF,
PlGF, and basic fibroblast growth factor (βFGF) were
tested for interaction with cancer type. Based on these
biomarker results, in vitro studies were performed to
confirm activity and evaluate mechanisms of action
engaged in a vascular sarcoma cell line.
Methods
Study design and dose escalation
Patients with advanced solid tumors refractory to stand-
ard therapy were enrolled in the phase I study. The re-
sults of this study were previously reported [9]. Patients
were ineligible if they were taking angiotensin converting
anzyme (ACE) inhibitors or angiotensin II receptor
blockers (ARBs).
Ang-(1–7) was administered by subcutaneous injection
daily for five consecutive days on a 21 day cycle. Treat-
ment was continued until disease progression or un-
acceptable toxicity. Planned dose cohorts were: 100
mcg/kg, 200 mcg/kg, 400 mcg/kg, 700 mcg/kg, and
1000 mcg/kg. A standard 3 + 3 dose-escalation strategy
was utilized. Maximum tolerated dose was defined as
the highest dose level at which no more than one of
six patients experienced a dose-limiting toxicity. This
study was approved by the Institutional Review Boardof Wake Forest University and was registered with the
National Cancer Institute PDQ Database and Clinical-
Trials.gov as NCT00471562.
Measurement of angiogenic hormone levels
Blood samples were drawn at time points immediately
prior to treatment as well as 1, 2, 3, 4, and 6 hours after
Ang-(1–7) administration. Samples were placed on ice
and plasma was extracted within 30 minutes of collec-
tion. Plasma samples were stored at −80°C prior to per-
forming biomarker analyses.
Hemolysis was assessed in all plasma samples and five
samples from three patients were excluded from bio-
marker modeling due to hemolysis. Aliquots of plasma
were assayed by a third party vendor (Pierce Biotechnol-
ogy, Woburn, MA). Searchlight ELISA technology was
used to prepare standard curves and quantify vascular
endothelial growth factor (VEGF), placental growth fac-
tor (PlGF), and basic fibroblast growth factor (βFGF).
Samples were blinded prior to shipping.
Cell culture
Ang-(1–7) and Ang II peptides were purchased from
Bachem (Basel, Switzerland), dissolved in sterile water,
and stored at −20°C. EOMA cell lines were purchased
from American Type Culture Collection (Manassas, VA)
and passaged as recommended. These cells were cul-
tured in Dulbecco’s minimal essential media (DMEM)
containing 10% fetal bovine serum (FBS). These cells
were cultured in a humidified incubator at 37°C with 5%
CO2 and passaged every 3 to 5 days.
Proliferation assays
Cellular proliferation was measured using the CellTiter
96 assay (Promega, Madison, WI). Assays were plated in
sextuplicate replicates in 96 well plates at a density of
1,000 cells per well. Basal absorbance activity was mea-
sured immediately prior to treatment. Cells were then
treated with Ang-(1–7), Ang II, or untreated as a con-
trol. Ang-(1–7) treatments were selected to represent a
range of clinically achievable concentrations. Absorbance
activity was measured after 72 hours in Ang-(1–7) trea-
ted, Ang II treated, and control cells. Proliferation was
calculated by subtracting the baseline absorbance from
absorbance measured following angiotensin or control
treatments. Proliferation rates in treated cells were nor-
malized to untreated control cells.
PCR arrays
EOMA cells were independently treated with Ang-(1–7)
at a concentration of 500 nM or untreated as a control.
Cells were harvested after 24 hours and RNA was ex-
tracted using TriReagent (Invitrogen, Carlsbad, CA).
RNA concentrations were measured, and RNA integrity
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angiogenesis and murine endothelial cell biology PCR
Arrays were purchased from SABiosciences (Frederick,
MD) and real-time RT-PCR reactions were performed
per the manufacturer’s protocol. A four-fold change in
gene expression was used to identify genes that were
regulated by Ang-(1–7) treatment.
Custom PCR Arrays (SABiosciences) were then de-
signed to measure genes identified by these initial PCR
Arrays as well as the VEGF and PlGF angiogenic hor-
mones in quadruplicate replicate. Real-time PCR reac-
tions were performed according to the manufacturer’s
protocol. Outlying values defined as those greater than 2
standard deviations from the mean were excluded from
statistical analyses. In cases where outlying values were
observed, PCR Array experiments were repeated to con-
firm the results.Statistical methods
Biomarker levels over time were modeled after log-
transformation, consideration of quadratic effects of
time (after centering), and adjustment for plasma drug
levels. A mixed effects model was used to tests for inter-
action of cancer type and biomarker effect. This poten-
tial interaction was controlled for presence or absence of
clinical benefit and plasma drug levels. In cases where a
significant interaction between biomarker and cancer
type was observed, univariate regression analyses were
performed separately for each cancer type. These regres-
sion analyses examined linear biomarker changes over
time following drug administration. Two sample t-tests
were performed to compare in vitro proliferation rates at
each dose level of Ang-(1–7) and Ang II to untreated
controls. Two sample t-tests were also performed to
compare PCR Array measurements from Ang-(1–7)
treated and untreated cells. All analyses were two-sided,
and a P-value < 0.05 was considered statistically signifi-
cant. P values were not corrected for multiple compari-
sons. Clinical biomarker analyses were performed using
SAS v9.1.3 (SAS Institute, Cary, NC) and Stata v10.1
(StataCorp, College Station, TX).Results
Patients
Eighteen patients were enrolled in the phase I study.
The results of this clinical trial were previously reported
[9]. Patient data were grouped according to cancer type
and characteristics of these groups are displayed in
Table 1. Cancers with only one case were grouped into
the category of “other.” This included one patient with
urachal carcinoma, one with anal carcinoma, one with
head and neck cancer, and one with lung cancer.Impact of hemolysis on plasma angiogenic hormone
concentrations
Hemolyzed plasma samples were excluded from prior
biomarker analyses in phase I study due to concerns that
hemolysis could alter angiogenic hormone concentra-
tions. To test this hypothesis, concentrations of VEGF,
PlGF, and βFGF were compared in hemolyzed and non-
hemolyzed blood samples. PlGF concentrations were sig-
nificantly increased in hemolyzed blood samples (9.2 vs
21.6 ng/mL, P= .01). Concentrations of βFGF appeared
to be increased but this effect did not reach statistical
significance (6.5 vs 17.5 ng/mL, P= .07). Concentrations
of VEGF were similar in hemolyzed and non-hemolyzed
blood samples (91.8 vs 92.8 ng/mL).
Biomarker analyses
A mixed effects model was established to examine
whether cancer type impacted the changes in angio-
genic biomarkers observed during the phase I study.
Tests for interaction were performed using pre- and
post-treatment biomarker measures according to cancer
type after controlling for dose cohort, the presence or ab-
sence of clinical response, and plasma drug level. Pre-
treatment levels of VEGF, PlGF and βFGF were not
significantly different according to cancer type. However,
post-treatment levels were significantly different accord-
ing to the type of cancer being treated for VEGF
(P= .001) and PlGF (P= .002).
Changes in VEGF and PlGF over time were then
assessed by univariate regression for each cancer type.
Angiogenic biomarker values at time 0 were used to
normalize values of subsequent time points for each pa-
tient. As shown in Figure 1, the only significant treat-
ment effect identified was a reduction in PlGF levels
over time in patients with metastatic sarcoma (P= .005).
Among the patients with sarcoma, the most significant
reduction in PlGF was observed in the patient with
metastatic hemangiopericytoma, a sarcoma of vascular
origin. This patient demonstrated a radiographic response
by Choi criteria (40% reduction in the sum of tumor
densities), which is often used to assess radiographic
responses for this type of sarcoma [10]. The radiographic
and biomarker changes for this patient are shown in
Figure 2A and 2B.
In addition, the patient with sarcoma who did not
benefit from treatment demonstrated a significant reduc-
tion in PlGF levels over time (P = .006). This supports
the hypothesis that cancer type predicts reduction in the
PlGF biomarker independent of clinical benefit.
In vitro sensitivity to Ang-(1–7)
The radiographic and biomarker findings highlighted
hemangiopericytoma as being sensitive to treatment with
Ang-(1–7). To study mechanisms of action, a murine
















100 mcg/kg 3 (17) 0 1 (33) 1 (33) 0 1 (25)
200 mcg/kg 3 (17) 1 (17) 0 1 (33) 1 (50) 0
400 mcg/kg 6 (33) 4 (73) 1 (33) 0 1 (50) 0
700 mcg/kg 6 (33) 1 (17) 1 (33) 1 (33) 0 3 (75)
Sex
Female 6 (33) 1 (17) 0 2 (67) 0 3 (75)
Male 12 (67) 5 (73) 3 (100) 1 (33) 2 (100) 1 (25)
Race
Black 3 (17) 1 (17) 0 1 (33) 0 1 (25)
White 15 (83) 5 (73) 3 (100) 2 (67) 2 (100) 3 (75)
Age 61.3 ± 12.0 60.6 ± 12.1 63.0 ± 13.1 59.9 ± 19.3 73.4 ± 0.5 55.7 ± 4.3
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this model is not ideal, it is frequently used to study the
biology of low grade vascular sarcomas [11-13].
As shown in Figure 3, treatment with clinically achiev-
able doses of Ang-(1–7) reduced the proliferation of
these cells at concentrations as low as 100 nM. The
structurally similar eight amino acid peptide, Ang II, was
applied to these cells at the same concentrations and did
not reduce proliferation. At high doses, Ang II treatment
stimulated proliferation of these cells. This indicates that
the growth suppressive effects of the Ang-(1–7) peptide
are due to a receptor mediated effect rather than a non-
specific toxic effect of the peptide.
Target gene analyses
To examine gene regulation responsible for the thera-
peutic effects of Ang-(1–7), murine PCR Arrays for an-





















Figure 1 Post-treatment PlGF changes according to cancer type
on day 1 of treatment. The lines shown represent trend lines for
median normalized values. Red color indicates a significant trend
(P < .05) based on the regression statistic. For cancer types with a
significant trend, median values and standard deviation error bars
are shown for each time point. * indicates a significant difference in
biomarker value (P < .05) compared to the time 0 biomarker value
based on a two-sample t-test.A total of 145 individual RNA species were measured by
real-time PCR and compared in EOMA cells treated with
Ang-(1–7) at a dose of 500 nM and untreated cells. Using
a cut-off of a four-fold change in expression, 18 genes
were identified as likely being regulated by Ang-(1–7).
Confirmatory PCR Arrays were performed using at
least four replicates for the purposes of statistical com-
parison. As shown in Figure 4, these analyses confirmed
statistically significant changes in 8 genes including re-
duced expression of HIF-1α (P < .001) and PlGF (P= .04).
Discussion
Phase I biomarker studies may fail to detect positive out-
comes if a variety of cancers are treated and biomarker
effects are dependent on cancer type. One approach to
overcome this challenge is to perform multi-institutional
phase I trials with eligibility restricted to a specific can-
cer type [14,15]. The approach taken for this study was
to treat patients with a variety of cancer types and then
test for the interaction of cancer type on biomarker out-
comes. This approach has advantages as opposed to
restricting eligibility when preclinical data have not
established the most promising cancer type for clinical
development.
Analyses of individual cancer types indicated that PlGF
was reduced in patients with sarcoma and did not detect
this effect in other cancer types. However, due to the
very limited sample size within each group (n = 2 to 6), it
cannot be concluded that biomarker changes do not
occur in other cancer types. Despite the limited statis-
tical power, identification of a significant biomarker ef-
fect in patients with sarcoma heightened our interest in
the use of this drug for the treatment of this disease.
Based on these biomarker findings and clinical out-
comes, a phase II trial of Ang-(1–7) has been initiated to
evaluate clinical activity and PlGF effects in patients with
metastatic sarcomas.
Pre Post















Figure 2 (A) Radiographic changes in a patient with metastatic hemangiopericytoma after two cycles of treatment. (B) Decreases in
PlGF concentrations are shown for the same patient on day 1 of Ang-(1–7) treatment. Error bars represent the standard deviations of repeated
ELISA analyses from a single plasma sample collected at each time point from this patient.
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pre-clinical model is essential for ongoing development
of this drug. The activity of Ang-(1–7) was tested in the

























Figure 3 Changes in the proliferation of murine endothelioma
(EOMA) cells following treatment with either Ang-(1–7) (black
bars) or Ang II (white bars) are shown. * indicates a significant
difference in proliferation (P < .05) compared to the proliferation rate
of untreated cells.with the most substantial biomarker changes. This work
revealed significant sensitivity at clinically achievable
doses which provides additional rationale for clinical
testing of this drug to treat hemangiopericytoma which
is a very rare disease. In addition, this model has pro-
vided a platform for investigating a clinically relevant
mechanism of action. This model uncovered HIF-1α as
a probable mediator of the therapeutic effects in this dis-
ease [16-18]. This unique mechanism of action provides
an attractive rationale for future combination of Ang-
(1–7) with other anti-angiogenic drugs.
Angiotensin-(1–7) [Ang-(1–7)] and angiotensin II
(Ang II) are structurally similar but bind distinct G-protein
coupled receptors with opposing physiologic functions
[3,19]. Ang II increases angiogenesis in animal models
and human diseases while Ang-(1–7) reduces angiogen-
esis [3]. Recent studies have linked the pro-angiogenic
effects of Ang II to upregulation of HIF-1α [20,21]. Taken
together with our findings that Ang-(1–7) decreases ex-
pression of this gene, HIF-1α expression appears to be a
key mediator of both the pro-angiogenic effects of Ang II
and the anti-angiogenic effects of Ang-(1–7).








































Figure 4 Changes in expression of target genes following treatment with Ang-(1–7). Error bars represent the 95% confidence interval.
* indicates a significant difference in target gene expression (P < .05) in Ang-(1–7) treated cells as compared to untreated cells.
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angiogenesis by increasing expression of vascular endo-
thelial growth factor (VEGF), placental growth factor
(PlGF), and other pro-angiogenic factors [16-18,22-24].
Some of these pro-angiogenic hormones may also feed-
back to regulate HIF-1α expression and function [25]. It
is likely that the reduction in plasma PlGF following
treatment with Ang-(1–7) is triggered by the reduction
of HIF-1α in tumors. Additional mechanistic studies are
planned as part of future work to confirm that a causal
relationship exists between these gene expression changes.
Conclusions
Exposure to high concentrations of Ang-(1-7) reduces the
production of pro-angiogenic peptides in transformed
vascular cells by reducing the expression of HIF-1α.
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